Skip to main content

Gossamer Bio, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

GOSS$10.65+9.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

PART I. FINANCIAL INFORMATION
Item 1Condensed Consolidated Financial Statements (unaudited)4
Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20254
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2026 and 2025 (unaudited)5
Condensed Consolidated Statements of Stockholders’ Deficit for the Three and Six Months ended June 30, 2026 and 2025 (unaudited)6
Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2026 and 2025 (unaudited)7
Notes to Unaudited Condensed Consolidated Financial Statements9
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations35
Item 3Quantitative and Qualitative Disclosures About Market Risk45
Item 4Controls and Procedures45
PART II. OTHER INFORMATION
Item 1Legal Proceedings46
Item 1ARisk Factors46
Item 2Unregistered Sales of Equity Securities and Use of Proceeds50
Item 3Defaults Upon Senior Securities50
Item 4Mine Safety Disclosures50
Item 5Other Information50
Item 6Exhibits50
Exhibit Index51
Signatures53
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.